Praxis Precision Medicines Inc. has disclosed inhibitors of potassium channel subfamily T member 1 (KCNT1) and its mutants reported to be useful for the treatment of Brugada syndrome, heart failure, muscle disorders, myocardial infarction, neurological disorders, pain, pruritus and psychiatric disorders.
Glycoprotein VI (GPVI) is a platelet collagen receptor involved in platelet activation and an emerging target for treating thrombotic disorders such as ischemic stroke. Data have been presented by University of Würzburg scientists regarding a humanized anti-GPVI Fab antibody, EMA-601, with unprecedented potency in vitro and in vivo.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has divulged myeloperoxidase inhibitors reported to be useful for the treatment of cardiovascular disorders.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified bridged pyridazine compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of sepsis.
Trio Medicines Ltd. has described β2-adrenoceptor (ADRB2) antagonists reported to be useful for the treatment of cancer, cerebral cavernous malformations, chronic heart failure, chronic obstructive pulmonary disease, hereditary hemorrhagic telangiectasia, migraine and asthma.
Atrial septal defect (ASD) is a congenital heart condition where the formation of the connection between the atrial chambers is defective, thus allowing left-to-right shunting and the consequent risk of atrial fibrillation, stroke and heart failure, among others.
Scientists from the Karolinska Institute have found two different types of cells that give rise to the fibroblasts that form fibrotic scars after spinal cord injury (SCI) depending on their location. In a study in mice, the researchers observed that pericytes acted in lesions that affect the gray matter and perivascular fibroblasts acted in the white matter.
Scientists at de Duve Institute focused on the genetic causes of vascular anomalies, more specifically on capillary malformation with dilated veins (CMDV).
Relay Therapeutics Inc. has disclosed three new programs from its existing preclinical pipeline, including two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor.
Merck Sharp & Dohme LLC has disclosed diacylglycerol acyltransferase type 2 (DGAT2) inhibitors reported to be useful for the treatment of atherosclerosis, type 2 diabetes, fibrosis, heart failure, hepatic steatosis, hypercholesterolemia, hyperlipidemia and obesity, among others.
RSS
